ArticleTherapeutic advances in medical oncology2026
NanoString profiling of DNA repair and apoptosis genes in testicular germ cell tumours with divergent chemotherapy outcomes.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Platinum-based chemotherapy cures most patients with advanced testicular germ cell tumours (TGCTs), yet a subset develops resistance or relapse. The molecular basis of platinum sensitivity and resistance remains unclear, particularly in archival formalin-fixed paraffin-embedded (FFPE) samples that limit broad genomic analyses. Objectives: To evaluate whether differential expression of genes involved in apoptosis, DNA repair, and cell-cycle regulation distinguish platinum-resistant TGCTs. Design: Retrospective exploratory molecular profiling study using archival TGCT tissue specimens. Methods: We profiled the expression of 30 genes related to apoptosis, DNA repair, and cell cycle regulation in 50 archival TGCT samples from 41 patients using the NanoString nCounter platform. Samples included platinum-sensitive, platinum-resistant, and post-chemotherapy teratomas. Platinum-resistant disease was defined as radiological progression and/or rising tumour markers after first line platinum-based chemotherapy. Platinum-sensitive cases included patients achieving complete response as well as those with residual teratoma requiring post-chemotherapy resection. Differential expression analysis and principal component analysis (PCA) were performed to compare transcriptional patterns across groups. Results: Post-chemotherapy teratomas demonstrated a distinct expression profile, characterised by lower Conclusions: NanoString-based targeted expression profiling identifies biologically distinct expression patterns in post-chemotherapy teratomas but did not reveal a unifying transcriptional signature associated with platinum resistance in TGCTs. These negative results underscore the multifactorial and heterogenous nature of platinum resistance and highlight the need for broader genomic, immune and epigenomic profiling to better elucidate mechanisms of platinum resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.